Open AccessTau PET correlates with different Alzheimer’s disease‐related features compared to CSF and plasma p‐tau biomarkers
Author(s) -
Ossenkoppele Rik,
Reimand Juhan,
Smith Ruben,
Leuzy Antoine,
Strandberg Olof,
Palmqvist Sebastian,
Stomrud Erik,
Zetterberg Henrik,
Scheltens Philip,
Dage Jeffrey L,
Bouwman Femke,
Blennow Kaj,
MattssonCarlgren Niklas,
Janelidze Shorena,
Hansson Oskar
Publication year - 2021
Publication title -
embo molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.923
H-Index - 107
eISSN - 1757-4684
pISSN - 1757-4676
DOI - 10.15252/emmm.202114398
Subject(s) - neuroimaging , concordance , alzheimer's disease neuroimaging initiative , cerebrospinal fluid , apolipoprotein e , pathology , medicine , psychology , cognition , dementia , cognitive decline , disease , positron emission tomography , alzheimer's disease , effects of sleep deprivation on cognitive performance , oncology , neuroscience
PET, CSF and plasma biomarkers of tau pathology may be differentially associated with Alzheimer's disease (AD)‐related demographic, cognitive, genetic and neuroimaging markers. We examined 771 participants with normal cognition, mild cognitive impairment or dementia from BioFINDER‐2 ( n = 400) and ADNI ( n = 371). All had tau‐PET ([ 18 F]RO948 in BioFINDER‐2, [ 18 F]flortaucipir in ADNI) and CSF p‐tau181 biomarkers available. Plasma p‐tau181 and plasma/CSF p‐tau217 were available in BioFINDER‐2 only. Concordance between PET, CSF and plasma tau biomarkers ranged between 66 and 95%. Across the whole group, ridge regression models showed that increased CSF and plasma p‐tau181 and p‐tau217 levels were independently of tau PET associated with higher age, and APOE ɛ4‐carriership and Aβ‐positivity, while increased tau‐PET signal in the temporal cortex was associated with worse cognitive performance and reduced cortical thickness. We conclude that biofluid and neuroimaging markers of tau pathology convey partly independent information, with CSF and plasma p‐tau181 and p‐tau217 levels being more tightly linked with early markers of AD (especially Aβ‐pathology), while tau‐PET shows the strongest associations with cognitive and neurodegenerative markers of disease progression.